Today's News |
Vancouver-based Aequus Announces Health Canada Approval for Zimed Preservative Free (Bimatoprost 0.03%)
Friday, January 6, 2023Company Profile | Follow Company
Vancouver, BC, January 6, 2023--(T-Net)--Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), announced that Health Canada has approved Zimed(R) PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension.
Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America.
Zimed(R) PF is the first prostaglandin analog (PGA) that is preservative free and offered in an easy-to-use multi-dose bottle in Canada. PGAs are commonly prescribed first-line to reduce IOP.
The vast majority of medications currently available include preservatives such as Benzalkonium Chloride (BAK). Chronic exposure to BAK has been found to increase the likelihood of experiencing Ocular Surface Disease (OSD) and reduce patient adherence.
Grant Larsen, Chief Commercial Officer, Aequus Pharmaceuticals
"We have heard from the eyecare professionals that there is a need for preservative-free alternatives," says Grant Larsen, CCO of Aequus Pharma. "The PGA market continues to grow year-over-year and we provided a new option for Canadian health care providers and their patients."
Zimed PF is contained in a unique multi-dose bottle that leverages a unidirectional valve and air filter technology to eliminates the need for a preservatives. In addition, this packaging format significantly reduces the amount of plastic used compared to single-use alternatives.
"Medicom is excited by this news and looks forward to launching Zimed(R) PF in the Canadian market with Aequus," says Simon Martin, CEO of Medicom. "Globally we have seen the strong uptake for Zimed(R) PF and pleased it will soon be available to Canadian patients."
Doug Janzen, Chairman and CEO, Aequus Pharmaceuticals
Doug Janzen, CEO of Aequus Pharma said, "We want to thank Medicom for their support through the approval process with Health Canada. This is our third product we've brought to Canada in this partnership. We look forward to launching Zimed(R) PF in 2023 and providing Canadians with more treatment options."
About AEQUUS PHARMACEUTICALS INC.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and optometry.
Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license, remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "potential" and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launches; the Company's expected revenues; the regulatory approval of its products; the Company's ability to attract international partners; and ongoing discussions with and the Company's ability to secure potential partners to further grow our product portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. [ MORE ] |
Other Recent Company News |
|||||||||||||||||||
|